AlphAIAlphAI — Financial news for AI agents
investors.comSEP 221 min read$AMGN

Amgen Boasts Success In Sjogren's; Shares Bound Higher

Amgen reported positive results for its experimental Sjogren's treatment, dazodalibep. The news drove shares above the 50-day moving average. Sjogren's syndrome is an autoimmune disease causing dryness and joint pain.

Original reporting
investors.com
Published Sep 22, 2026, 3:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 4:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$AMGN
Bullish
high confidence
Mentioned
$AMGN
Relevance
8/10
AlphAI data visualization · based on investors.com
Decision brief

The 30-second read

$AMGNBullishHigh
01

Why it matters

The data suggest a statistically significant improvement, prompting immediate market reaction.

02

Market read

First‑report positive trial data for a major biotech can trigger rapid price moves and affect sector sentiment.

03

What to watch

Regulatory timeline and competitive pipeline for Sjogren's treatments are still uncertain.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Amgen announced early trial results for dazodalibep, an experimental therapy for Sjogren's syndrome, an autoimmune condition with limited treatment options.

Company-level read

Ticker impact

$AMGNBullishHigh confidence
Context

Amgen reported positive Phase 2 data for its experimental Sjogren's treatment dazodalibep, causing the stock to break above its 50‑day line.

Expected impact

Potential 5‑10% rally in the next few days.

Evidence & confidence

Biotech stocks typically react strongly to early‑stage positive data, and Amgen's large market cap amplifies the move.

Market effects

Sector

Positive Sjogren's data could lift other biotech firms developing autoimmune therapies.

Regional

U.S. biotech sector may see modest gains in early trading.

Global

May influence global investors tracking US biotech pipeline progress.

Counterpoint

What could challenge this read

If later-phase data fail to confirm efficacy, the rally could reverse sharply.

Key entities

  • Company
    Amgen

    US‑listed biotech firm (ticker AMGN).

  • Drug
    dazodalibep

    Experimental treatment for Sjogren's syndrome.

Read at source← All news

Also covered by

2 outlets

Related articles

SEP 22
$AMGNMedAI 8/10

AMGN Looks 10.5% Overvalued on GF Value™ Amid Dividend Sustainab

Amgen (AMGN) reported preliminary positive Phase 3 trial results for dazodalibep, a treatment for systemic Sjogren's syndrome. Citi maintains a Neutral rating with a $405 price target. The stock offers a 2.44% dividend yield, a 44% payout ratio, and a 7.1% 3-year dividend growth rate. GF Value™ suggests the stock is 10.5% overvalued, while the GF Score™ is 86/100, reflecting strong profitability and growth but weaker financial strength and momentum.

gurufocus.com2 min
SEP 22
$AMGNMedAI 9/10

Amgen’s dazodalibep meets primary endpoint in Sjögren’s trial

Amgen (AMGN) reported that its Phase 3 trial of dazodalibep met the primary endpoint in treating Sjögren’s disease, showing significant improvement at Week 48. The study enrolled 621 patients. Dazodalibep is not yet FDA-approved. Amgen plans to share detailed data at a future medical meeting. The company's Phase 3 OASIZ 303 study is expected to complete in Q4 2026.

investing.com2 min
SEP 22
$AMGNHighAI 8/10

Why is Amgen stock surging today?

Amgen (AMGN) stock rose 3.5% after its Phase 3 OASIZ 301 study of dazodalibep met primary endpoints, showing improvement in systemic Sjögren’s disease. Analysts maintained varied ratings. The broader market saw modest gains.

investing.com2 min
SEP 22
$AMGNHighAI 8/10

Amgen’s dazodalibep Phase 3 trial clears Sjögren’s hurdle

Amgen (AMGN) reported that its Phase 3 trial for dazodalibep met its primary endpoint in treating moderate-to-severe systemic Sjögren’s disease, showing statistically significant improvement. The study enrolled 651 participants, and the drug is currently under review. Amgen's revenue was $10.054 billion in Q2 2026, with net income of $2.375 billion. A second Phase 3 trial, OASIZ 303, is expected to complete in Q4 2026.

financial-news.co.uk2 min
SEP 22
$AMGNHighAI 8/10

Amgen stock surges on positive Sjögren’s trial results

Amgen Inc (AMGN) shares rose 4% premarket after positive Phase 3 trial results for dazodalibep in treating Sjögren’s disease. The study met its primary endpoint, showing significant improvement in disease activity. Sjögren’s has no FDA-approved treatments. Adverse events were mild to moderate. Amgen plans to present detailed data at a future medical meeting.

investing.com2 min